An American foreigner came to China from thousands of miles away to successfully start a business in this strange land. Kung Fu pays off! The A-share Science and Technology Innovation Board will usher in the first biotech giant with a market value of more than 200 billion yuan listed on the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange "A+H+N".
The second high-priced stock of the year is here! BeiGene (688235) issued an IPO price of 192.60 yuan per share on the Science and Technology Innovation Board, with an online subscription date of December 2 and a subscription code of "787235".
Hillhouse has regained its position, and BeiGene is about to land on the Science and Technology Innovation Board
BeiGene executive team
The Shanghai Stock Exchange Science and Technology Innovation Board is about to usher in the second high-priced stock of the year, and December 2 is the new day. The world's first biotechnology company to be listed on the NASDAQ, the Hong Kong Stock Exchange and the Shanghai Stock Exchange "A+H+N" is about to be born, and the IPO of the BeiGene Science and Technology Innovation Board has been approved by the CSRC and will be listed in the three places.
According to the issuance announcement disclosed by BeiGene on the evening of November 30, the new share issue price is 192.60 yuan per share, the online subscription date is December 2, and the online subscription code is "787235". On November 16, the China Securities Regulatory Commission (CSRC) issued an announcement agreeing to the registration of BeiGene's initial public offering of shares on the Star Market in accordance with legal procedures, and with the launch of the new market on December 2, BeiGene's landing on the domestic A-share market officially entered the countdown time.
BeiGene is an R&D company established in Beijing in 2010. In 2016, BeiGene raised a US$182 million IPO, becoming the first Chinese biotech company to list on the NASDAQ. A year earlier, BeiGene had established its first office in Cambridge, Massachusetts, and officially entered the U.S. market. In 2018, it landed on the Hong Kong Stock Exchange, raising US$902 million in IPO funds, achieving dual Tier 1 listings on the NASDAQ and Hong Kong Stock Exchange in the United States. In December 2021, it will be listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange.
As a red-chip enterprise established in the Cayman Islands and listed on the NASDAQ Exchange and the Hong Kong Stock Exchange, BeiGene has planned a specific company positioning this time: "With a market value of more than 20 billion yuan, and has independent research and development, international leading technology, strong scientific and technological innovation capabilities, and is in a relatively advantageous position in the same industry competition." ”
As of the opening of The Hong Kong stock market on December 1, BeiGene Hong Kong stock (06160. HK) rose 2.88% to HK$214.200 with a market capitalization of HK$260.1 billion, and with U.S. stocks closing at US$347.53/ADS, the company's total market capitalization has reached RMB210 billion.
BeiGene founder Ou Leiqiang (left) and founder Dr. Wang Xiaodong attend the 2016 NASDAQ listing ceremony
Since its listing on the NASDAQ Global Select Market in February 2016, BeiGene has been a "big bull stock", with a stock price that has not fallen in a year and has gained more than 11 times. It is worth mentioning that whether it is BeiGene's listing in the United States or the Hong Kong stock market, the well-known investment institution Hillhouse is a heavy investment, BeiGene is Hillhouse's first heavy stock in the US stock position, and it is also a heavy position in Hong Kong stocks, as of the end of June this year, Hillhouse's shareholding ratio is as high as 11.13%.
In November this year, BeiGene was included in a number of FTSE Russell Indexes, and once it successfully "Denko" on the Shanghai Stock Exchange a few days later, it was a lot of money to make a lot of money in BeiGene Hillhouse.
BeiGene, which originated in Beijing, is a group of scientists and developers who have discovered new anti-cancer treatments and helped improve patient accessibility in China. The company has been established for 11 years, with a global team, rich product pipeline, solid partnerships and commercial products. As they say: "In BeiGene, we cross borders. ”
In 2017, BeiGene launched the first global phase 3 clinical trial of zebutinib and collaborated with Celgene Corporation ("Bristol-Myers Squibb") on terelizumab on terelizumab; Acquired the commercial team of Xinji and the commercial products of Vidasa ®, Ruifumei ® and Abraxane® in China. In 2019, it reached a global tumor strategic cooperation with Amgen, and Angave ® is the registered trademark of Amgen.
In 2019, Baiyueze ® (Zebutinib capsules) was approved for the marketing by the US Food and Drug Administration (FDA) for the first time, and Baiyuezean ® (terelizumab injection) became the first product to be approved in China. In 2020, Baiyue ze was ® approved for listing in China for the first time, and Bai Zean ® was approved for listing in China for the second time. This year, BeiGene reached a global strategic cooperation with Novartis, and Bai Zean ® was approved for listing in China for the third time.
BeiGene Co-Founder, Chairman and CEO Ou Lei qiang (screen left) and Novartis Group Global CEO Dr. Wan Sihan (screen right)
As an innovative biotechnology company, BeiGene is at the forefront of domestic pharmaceutical companies in its R&D investment. From 2018 to 2020, the company's R&D investment was 4.597 billion yuan, 6.588 billion yuan and 8.943 billion yuan respectively, ranking first among domestic pharmaceutical companies for three consecutive years.
Deep ploughing in the field of tumors has enabled BeiGene to achieve high growth in the past 11 years. The prospectus also said that BeiGene itself has very strong clinical development capabilities, basically achieved "decrocroization", and no longer relies on third-party clinical institutions. According to reports, BeiGene's preclinical, clinical and commercial pipelines have been able to cover more than 80% of the world's high-incidence cancer types.
Incidentally, BeiGene's IPO issuance plan introduces a "green shoe" mechanism. That is, the issuer grants the investment bank an option not to exceed 15% of the initial number of shares to be issued. This move is naturally conducive to maintaining the stability of the stock price in the early stage of listing.
BeiGene launched the development of Bai Zean ® in 2012 and successfully brought this global high-quality PD-1 monoclonal antibody to the market in more than seven years. In December 2020, Bai Zean ® was included in the new version of the national medical insurance drug list. As the first to carry out clinical trials overseas and currently has the largest number of domestic PD-1 monoclonal antibodies in the world, Bai Zean ® has a total of 15 registered clinical trials around the world, covering lung cancer, liver cancer, esophageal squamous cell carcinoma, gastric cancer, nasopharyngeal cancer and other cancers, and has enrolled more than 7,700 patients worldwide, including about 2,500 patients in 20 countries and regions outside the Chinese mainland.
It is foreseeable that after the successful listing of "A+H+N" in BeiGene, the global "going to sea" layout will be a major attraction.
China has better chances! An American foreigner came to China from afar
BeiGene co-founder, chairman and CEO Ou Lei qiang
"China has a better chance!" An American foreigner came to China from afar. Mr. John Oyler, co-founder, chairman and CEO of BeiGene, is actually an American foreigner who gave himself a resounding Chinese name - Ou Leiqiang.
Dr. Xiaodong Wang, another founder of BeiGene and chairman of the Scientific Advisory Board, was a researcher at the Howard Hughes Institute of Medicine and a Distinguished Principal Professor of Biomedical Sciences at the University of Texas Southwestern Medical Center before the company was founded in 2010. At that time, Wang Xiaodong, a scientist of Chinese descent, originally invited Ou Leiqiang to start a business in the San Francisco Bay Area, but Ou Leiqiang gave Wang Xiaodong an unexpected direction: "China has better opportunities!" ”
At this point, an American foreigner John Oyler and a Chinese-American scientist Wang Xiaodong have become the "best partner" in BeiGene, a 200 billion red-chip biotechnology giant. Not long ago, the 2021 Hurun Rich List was announced, and the 53-year-old Founder of BeiGene, Ou Leiqiang, was listed with a net worth of 16 billion yuan. An American foreigner appearing on China's rich list cannot be said to be a miracle!
John Olyer, who holds an MBA from Stanford University and a B.A. from MIT, graduated in mechanical engineering from MIT and began his career as a business consultant at McKinsey & Company. In 1997, he founded telephia and served as president, which was acquired by Nielsen in 2007.
From 1997 to 1998, he held the position of Co-CEO of Genta, a biomedical company focused on oncology, and from 2002 to 2004, he was CEO of Galenea, a biopharmaceutical company founded at the Massachusetts Institute of Technology, which focuses on the development of innovative therapies for diseases of the central nervous system. From 2005 to 2009, he was president and CEO of Biotech, a pharmaceutical R&D outsourcing company, which unexpectedly was acquired again in 2010, which led to the establishment of The "Karma Meeting" with Wang Xiaodong in Beijing.
Dr. Xiaodong Wang, Co-Founder of BeiGene and Chairman of the Scientific Advisory Committee
Speaking of BeiGene, in addition to Ou Leiqiang, who has come to China from thousands of miles, Dr. Wang Xiaodong, who is now the co-founder of BeiGene and the chairman of the Scientific Advisory Committee, is a legend that must be mentioned.
In the past 10 years, Wang Xiaodong has achieved three enterprises and three entrepreneurs. In addition to BeiGene and American foreigner Oreqiang, the biopharmaceutical company Clover was also set up in Chengdu in 2007 with the help of friends. In addition, the recently established biopharmaceutical company "Vetai Ruilong", which focuses on the research and development of First-in-class chemical drugs, was jointly founded by Dr. Wang Xiaodong, director of the Beijing Institute of Life Sciences, academician of the American Academy of Sciences, foreign academician of the Chinese Academy of Sciences, and Dr. Zhang Zhiyuan, a senior researcher of the Beijing Institute of Life Sciences, located in Zhongguancun Life Science Park, Changping District, Beijing.
There is no doubt that BeiGene has broken the record of zero chinese innovative drugs going to sea, and its development of zebutinib has become the first new anti-cancer drug approved and commercialized abroad in China, which is naturally one of dr. Wang Xiaodong's proud achievements.
Dr. Wang Xiaodong
Before joining forces with Ou Leiqiang to found BeiGene in 2010, Dr. Wang Xiaodong was already a well-known figure in the domestic biomedical circle, and he had three praiseworthy labels: "almost unparalleled figure in the field of apoptosis", "The first person in China to be an academician of the American Academy of Sciences after the reform and opening up", and "Director of the Beijing Institute of Life Sciences".
Incidentally, Shi Yigong, president of Westlake University, also said that it was Wang Xiaodong's words that touched his thoughts of returning to China.
Wang Xiaodong, whose ancestral home is Henan, is an alumnus of the 1980 class of Henan Normal University Affiliated High School, and was admitted to the Biology Department of Beijing Normal University in 1980, scoring more than 90 points in each professional course in his freshman and sophomore years. By his junior year, he focused on his favorite English. In 1985, Wang Xiaodong went to the United States to study, and in 1991, he received his Ph.D. in biochemistry from the University of Texas Southwestern Medical Center, where he chose the Department of Molecular Genetics for postdoctoral research. At that time, Wang Xiaodong was followed by Joseph Goldstein and Michael Brown, winners of the 1985 Nobel Prize in Physiology or Medicine.
Famous teachers out of high apprentices! In 1995, Wang Xiaodong established his own laboratory and began to engage in research on apoptosis. He was 41 years old when he was elected to the National Academy of Sciences in April 2004. Two years later, he won the Shaw Prize for Life Sciences and Medicine. "Director of Beijing Institute of Life Sciences" is an important milestone in his life course, in 2003, Wang Xiaodong was invited back to China to establish the Beisheng Institute.
In 2010, at a party, Wang Xiaodong and Ou Leiqiang met, when Ou Leiqiang had just resigned as the president and CEO of the company because of the acquisition of Baonuo Technology by PPD, and the two hit it off, giving birth to a pair of entrepreneurial "golden partners" in BeiGene.
Wang Xiaodong once said that I often joke that I am a scientist in front of entrepreneurs and an entrepreneur in front of scientists. In such a cross-border, he also made an analogy: "It's a bit like climbing a mountain, when we reach the top of the mountain and see the most beautiful scene, then what's next?" Is to continue down, no way to go but down. ”
This article is a wave of original content
Unauthorized reproduction and sending of excerpts in any form is strictly prohibited